Article
type: Class

Document
type: Class

Anualidad
type: Class

Academic Article
type: Class

Information Content Entity
type: Class

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

2015
type: Class

individual
type: Document
rights: termsOfUse
date: 2026-08-29T09:25:25
publisher: Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: Long-term results of the Spanish GCR-3 phase II randomized trial
label: RDF description of Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: Long-term results of the Spanish GCR-3 phase II randomized trial - http://research.umh.es/vivo/pub/articulo/161691

Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: Long-term results of the Spanish GCR-3 phase II randomized trial
type: Document
ARG_2000028: 161691 vcard
type: Generically Dependent Continuant
page end: 1728
has publication venue: ANNALS OF ONCOLOGY
most specific type: Academic Article
type: Information Content Entity
type: Article
type: Anualidad
related by: Autor:153379-Artículo:161691
date time value: 161691 pubdate
type: Thing
type: 2015
type: Continuant
type: Academic Article
most specific type: 2015
type: Entity
page start: 1722

ANNALS OF ONCOLOGY
type: Information Content Entity
type: Continuant
type: Journal
type: Periodical
type: Thing
type: Collection
type: Entity
type: Generically Dependent Continuant
publication venue for: Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: Long-term results of the Spanish GCR-3 phase II randomized trial

Autor:153379-Artículo:161691
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: Long-term results of the Spanish GCR-3 phase II randomized trial